[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 64 of about 64
5. Dhanwal DK, Vyas A, Sharma A, Saxena A: Hypothalamic pituitary abnormalities in tubercular meningitis at the time of diagnosis. Pituitary; 2010 Dec;13(4):304-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This prospective study included 75 untreated adult patients with TBM diagnosed as "definite", "highly probable" and "probable" TBM by Ahuja's criteria and in clinical stage 1, 2 or 3 at the time of presentation to hospital.
  • [MeSH-minor] Adolescent. Adult. Female. Follicle Stimulating Hormone / blood. Humans. Hydrocortisone / blood. Luteinizing Hormone / blood. Magnetic Resonance Imaging. Male. Prolactin / blood. Thyrotropin / blood. Thyroxine / blood. Triiodothyronine / blood. Young Adult

  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Postgrad Med J. 2006 Apr;82(966):259-66 [16597813.001]
  • [Cites] Ann Intern Med. 1993 May 1;118(9):701-6 [8460856.001]
  • [Cites] J Assoc Physicians India. 2007 Jun;55:453-6 [17879504.001]
  • [Cites] Chest. 2002 Nov;122(5):1784-96 [12426284.001]
  • [Cites] Eur J Endocrinol. 2009 Jan;160(1):9-16 [18952762.001]
  • [Cites] Br Med J. 1965 Oct 9;2(5466):839-43 [5827798.001]
  • [Cites] Eur J Endocrinol. 2008 Jan;158(1):3-9 [18166811.001]
  • [Cites] Tuber Lung Dis. 1994 Apr;75(2):149-52 [8032049.001]
  • [Cites] QJM. 2003 Sep;96(9):643-8 [12925719.001]
  • [Cites] J Assoc Physicians India. 1998 Mar;46(3):322 [11273360.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Apr;94(4):1059-67 [19349469.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Mar;81(3):1169-72 [8772595.001]
  • [Cites] Indian Pediatr. 1993 May;30(5):607-23 [8282387.001]
  • [Cites] Pituitary. 2008;11(3):313-5 [17786560.001]
  • [Cites] N Engl J Med. 1996 Oct 17;335(16):1206-12 [8815944.001]
  • [Cites] Horm Metab Res. 2009 Nov;41(11):834-9 [19585406.001]
  • [Cites] Neurol India. 2003 Dec;51(4):548-50 [14742947.001]
  • [Cites] Neurology. 2007 May 15;68(20):1745 [17502561.001]
  • [Cites] Am J Dis Child. 1969 Dec;118(6):903-8 [5353020.001]
  • [Cites] Eur J Endocrinol. 2000 Jul;143(1):1-13 [10870025.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Dec;75(6):1562-70 [1464665.001]
  • [Cites] JAMA. 1979 Jan 19;241(3):264-8 [102806.001]
  • [Cites] Crit Care Med. 2002 Jun;30(6):1267-73 [12072680.001]
  • [Cites] Crit Care Clin. 2006 Jan;22(1):105-18, vii [16399022.001]
  • (PMID = 20495961.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 06LU7C9H1V / Triiodothyronine; 9002-62-4 / Prolactin; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; 9002-71-5 / Thyrotropin; Q51BO43MG4 / Thyroxine; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


6. Nielsen OS, Reichardt P, Christensen TB, Pink D, Daugaard S, Hermans C, Marreaud S, van Glabbeke M, Blay J, Judson I: Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. Eur J Cancer; 2006 Sep;42(14):2303-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Male. Middle Aged. Neoplasm Metastasis. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16891112.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


7. Dogan EA, Usta BE, Bilgen R, Senol Y, Aktekin B: Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy. Epilepsy Behav; 2008 Jul;13(1):156-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy.
  • OBJECTIVE: The aim of the study described here was to investigate the efficacy, tolerability, and side effects of oxcarbazepine (OXC) monotherapy in newly diagnosed, previously untreated adult and elderly patients with partial epilepsy.
  • CONCLUSION: Although the limitations of our study include its open-label design, the results suggest that OXC monotherapy may be regarded as an effective first-line monotherapy option for adult and elderly patients with partial epilepsy, but has low efficacy in patients with cerebral tumors.
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Drug Evaluation. Female. Humans. Male. Middle Aged. Prospective Studies. Retrospective Studies

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • Hazardous Substances Data Bank. OXCARBAZEPINE .
  • Hazardous Substances Data Bank. CARBAMAZEPINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331816.001).
  • [ISSN] 1525-5069
  • [Journal-full-title] Epilepsy & behavior : E&B
  • [ISO-abbreviation] Epilepsy Behav
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 33CM23913M / Carbamazepine; VZI5B1W380 / oxcarbazepine
  •  go-up   go-down


8. Mazziotti G, Bianchi A, Bonadonna S, Nuzzo M, Cimino V, Fusco A, De Marinis L, Giustina A: Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J Bone Miner Res; 2006 Apr;21(4):520-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy.
  • This cross-sectional study shows that a high number of untreated adult patients with GHD develop radiological vertebral deformities.
  • MATERIALS AND METHODS: One hundred seven adult hypopituitary patients (67 males and 40 females; mean age, 47 years; range: 16-81 years) with severe GHD and 130 control subjects (39 males, 91 females; mean age: 58.9 years; range: 26-82 years) were evaluated for BMD (DXA) and vertebral deformities (quantitative morphometric analysis).
  • The fracture prevalence, as well as the fracture number, was significantly higher in untreated versus treated patients (78.6% versus 53.8%; chi2: 6.7; p = 0.009), although the two groups of patients did not show any significant difference in median T score.
  • In untreated GHD patients, the prevalence of vertebral deformities was correlated with T score (p = 0.002) and duration of disease (p = 0.003).
  • CONCLUSIONS: This cross-sectional study reports high prevalence of vertebral radiological deformities in adult patients with untreated GHD.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bone Density / physiology. Cross-Sectional Studies. Female. Fractures, Bone / epidemiology. Humans. Male. Middle Aged. Prevalence. Risk Factors

  • Genetic Alliance. consumer health - Spinal Deformities.
  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16598371.001).
  • [ISSN] 0884-0431
  • [Journal-full-title] Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • [ISO-abbreviation] J. Bone Miner. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


9. Slotte C, Lundgren D, Sennerby L: Bone morphology and vascularization of untreated and guided bone augmentation-treated rabbit calvaria: evaluation of an augmentation model. Clin Oral Implants Res; 2005 Apr;16(2):228-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone morphology and vascularization of untreated and guided bone augmentation-treated rabbit calvaria: evaluation of an augmentation model.
  • To our knowledge, however, few studies on the characteristics of the untreated calvaria regarding bone density, vessel topography, and their intra/interindividual variations and associations are available.
  • The aims of this investigation were to (1) map the large vessel topography of the skull vault, (2) describe the parietal bones of the adult rabbit histologically and morphometrically, and (3) histologically compare untreated parietal bone with parietal bone that had been treated with a GBA device.
  • MATERIAL AND METHODS: Ten adult untreated rabbits were microangiographed.
  • In addition, sections from 14 GBA-treated rabbit skulls (of the same race, sex and age as the untreated animals) served as reference specimens for comparison.
  • Hollow connections were frequently found in both the outer and inner cortical plates in both the untreated and the GBA-treated specimens.
  • The morphometric measurements revealed similar proportions of cortical, trabecular, and marrow areas in the right and left untreated bones.
  • Bone density was similar in the right and left untreated and GBA-treated specimens, as was the frequency and width of hollow connections through the cortical bone plates.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15777333.001).
  • [ISSN] 0905-7161
  • [Journal-full-title] Clinical oral implants research
  • [ISO-abbreviation] Clin Oral Implants Res
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


10. Morita Y, Kanamaru A, Miyazaki Y, Imanishi D, Yagasaki F, Tanimoto M, Kuriyama K, Kobayashi T, Imoto S, Ohnishi K, Naoe T, Ohno R: Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group. Int J Hematol; 2010 Jan;91(1):97-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group.
  • A total of 120 patients with high-risk myelodysplastic syndrome (MDS) and AML progressed from MDS (MDS-AML) were registered in a randomized controlled study of the Japan Adult Leukemia Study Group (JALSG).
  • Untreated adult patients with high-risk MDS and MDS-AML were randomly assigned to receive either idarubicin and cytosine arabinoside (IDR/Ara-C) (Group A) or low-dose cytosine arabinoside and aclarubicin (CA) (Group B).
  • [MeSH-major] Aclarubicin / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cytarabine / administration & dosage. Idarubicin / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Female. Humans. Japan. Male. Middle Aged. Remission Induction. Risk Factors. Survival Analysis. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • Hazardous Substances Data Bank. CYTARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Med. 2005;56:1-16 [15660498.001]
  • [Cites] Blood. 2004 Jul 15;104(2):579-85 [15039286.001]
  • [Cites] Leuk Lymphoma. 2006 Apr;47(4):599-602 [16690517.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 May;8(5):785-98 [18471050.001]
  • [Cites] Lancet Oncol. 2009 Mar;10(3):223-32 [19230772.001]
  • [Cites] Leukemia. 2007 Jul;21(7):1357-62 [17508002.001]
  • [Cites] Int J Hematol. 2000 Aug;72(2):151-6 [11039662.001]
  • [Cites] Leuk Res. 2009 Aug;33(8):1024-8 [19185917.001]
  • [Cites] Leukemia. 1995 Jan;9(1):10-4 [7531259.001]
  • [Cites] Int J Hematol. 2000 Aug;72(2):200-5 [11039669.001]
  • [Cites] Br J Haematol. 1982 Jun;51(2):189-99 [6952920.001]
  • [Cites] Leuk Res. 1992;16(1):109-15 [1732663.001]
  • [Cites] Leukemia. 2005 Mar;19(3):396-401 [15674354.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):345-52 [17559141.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Apr;13(4):454-62 [17382251.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2079-88 [9058730.001]
  • [Cites] Crit Rev Oncol Hematol. 2001 Dec;40(3):229-38 [11738946.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Ann Hematol. 1992 Oct;65(4):162-8 [1420504.001]
  • [Cites] Br J Haematol. 2000 Jan;108(1):93-5 [10651730.001]
  • [Cites] Blood. 2008 Aug 1;112(3):895-902 [18497321.001]
  • (PMID = 20047095.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 74KXF8I502 / Aclarubicin; ZRP63D75JW / Idarubicin
  •  go-up   go-down


11. Hamurcu Z, Dönmez-Altuntas H, Patiroglu T: Basal level micronucleus frequency in stimulated lymphocytes of untreated patients with leukemia. Cancer Genet Cytogenet; 2008 Jan 15;180(2):140-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal level micronucleus frequency in stimulated lymphocytes of untreated patients with leukemia.
  • Structural chromosomal aberrations have been described in various types of human leukemia.
  • The present study investigated micronucleus (MN) frequency in mitogen-stimulated peripheral blood lymphocytes from 20 newly diagnosed and untreated leukemia patients: 4 with acute lymphoblastic leukemia (ALL), 10 with acute myeloid leukemia (AML), and 6 with chronic lymphocytic leukemia (CLL).
  • The mean MN frequency for untreated patients was 3.65 +/- 1.47 in ALL, 3.55 +/- 1.24 in AML, 3.03 +/- 1.05 in CLL.
  • No differences in MN frequency were seen between leukemia types ALL, AML, and CLL (P = 0.503).
  • The mean basal MN frequency for all patients, regardless of leukemia type, was 3.41 +/- 1.19, which was significantly higher (P = 0.001) than that of 20 age-matched control subjects, 1.87 +/- 0.75.
  • Although no significant relationship was found between age and MN frequency in patients with leukemia (r = 0.050; P = 0.835), the MN frequency in the lymphocytes of healthy control increased regularly and significantly with age (r = 0.531; P = 0.016).
  • These data indicate that the increased baseline MN frequency in lymphocytes of untreated patients with leukemia may reflect genomic instability or deficiency of DNA repair capacity.
  • [MeSH-major] Leukemia / genetics. Lymphocytes / metabolism. Micronuclei, Chromosome-Defective / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Case-Control Studies. Child. Child, Preschool. Female. Humans. Male. Micronucleus Tests. Middle Aged

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18206540.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Leubner KD, Chop WM Jr, Ewigman B, Loven B, Park MK: Clinical inquiries. What is the risk of bowel strangulation in an adult with an untreated inguinal hernia? J Fam Pract; 2007 Dec;56(12):1039-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical inquiries. What is the risk of bowel strangulation in an adult with an untreated inguinal hernia?
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Humans. Middle Aged. Patient Selection. Practice Guidelines as Topic. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18053445.001).
  • [ISSN] 1533-7294
  • [Journal-full-title] The Journal of family practice
  • [ISO-abbreviation] J Fam Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


13. Jenkinson MD, Smith TS, Haylock B, Husband D, Shenoy A, Vinjamuri S, Walker C, Pietronigro D, Warnke PC: Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma. J Neurooncol; 2010 Aug;99(1):103-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. THALLIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2000 Jan;2(1):45-59 [11302254.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1351-6 [2689399.001]
  • [Cites] J Neurooncol. 2003 May;62(3):251-8 [12777076.001]
  • [Cites] Neurosurg Focus. 2003 Feb 15;14(2):e2 [15727423.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7182-91 [15534091.001]
  • [Cites] Neuroradiology. 2003 Jun;45(6):373-6 [12719953.001]
  • [Cites] J Neurosurg. 2005 Feb;102(2):267-75 [15739554.001]
  • [Cites] Cancer. 1986 Apr 1;57(7):1276-80 [3948112.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Neoplasia. 2003 Jan-Feb;5(1):9-16 [12659665.001]
  • [Cites] Nat Med. 1997 Dec;3(12):1362-8 [9396606.001]
  • [Cites] J Cereb Blood Flow Metab. 1991 Sep;11(5):753-61 [1874807.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Neoplasia. 2003 Jan-Feb;5(1):17-22 [12659666.001]
  • [Cites] Stroke. 1977 Jan-Feb;8(1):51-7 [13521.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1382-90 [10451443.001]
  • [Cites] Can J Neurol Sci. 1999 Feb;26(1):18-22 [10068802.001]
  • [Cites] CNS Drugs. 2001;15(9):719-43 [11580310.001]
  • [Cites] J Neurosurg. 2001 Sep;95(3):379-80 [11565856.001]
  • [Cites] Neuroradiology. 2006 Oct;48(10):703-13 [16937145.001]
  • [Cites] Ann Neurol. 2005 Jan;57(1):136-9 [15622544.001]
  • [Cites] Neurosurgery. 1988 Mar;22(3):465-73 [2452376.001]
  • [Cites] Neuro Oncol. 2001 Oct;3(4):241-5 [11584893.001]
  • [Cites] Cancer Res. 1988 Aug 15;48(16):4489-92 [3396000.001]
  • [Cites] Magn Reson Imaging. 2007 Apr;25(3):303-10 [17371718.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):225-38 [15980973.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Feb;27(2):402-8 [16484419.001]
  • [Cites] J Nucl Med. 1998 May;39(5):786-90 [9591575.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7852-9 [15585617.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):1-8 [11763417.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):29-38 [18082451.001]
  • [Cites] Mutat Res. 1990 Nov-Dec;233(1-2):117-26 [2233793.001]
  • [Cites] Acta Oncol. 1995;34(3):335-8 [7779419.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):99-104 [7721644.001]
  • [Cites] Lancet Oncol. 2008 May;9(5):453-61 [18452856.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • (PMID = 20063175.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0Z5B2CJX4D / Fluorodeoxyglucose F18; AD84R52XLF / Thallium; U68WG3173Y / Carmustine
  •  go-up   go-down


1
Advertisement
4. Ginsberg S, Laron Z, Bed MA, Vaisman N: The obesity of patients with Laron Syndrome is not associated with excessive nutritional intake. Obes Res Clin Pract; 2009 Mar;3(1):1-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUMMARY: To study the metabolic parameters which may affect the excessive weight of treated and untreated patients with Laron Syndrome.
  • SUBJECTS: Nine untreated adult subjects with Laron Syndrome (6 female subjects, 3 male subjects) aged 28-53 years and 4 girls with Laron Syndrome treated by insulin-like growth factor-I (IGF-I) 120-150 μg/kg/d were included in the study.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 Asian Oceanian Association for the Study of Obesity . Published by Elsevier Ltd. All rights reserved.
  • (PMID = 24345535.001).
  • [ISSN] 1871-403X
  • [Journal-full-title] Obesity research & clinical practice
  • [ISO-abbreviation] Obes Res Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


15. Tektas OY, Hammer CM, Danias J, Candia O, Gerometta R, Podos SM, Lütjen-Drecoll E: Morphologic changes in the outflow pathways of bovine eyes treated with corticosteroids. Invest Ophthalmol Vis Sci; 2010 Aug;51(8):4060-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The TM of four adult Braford cow eyes treated with 0.5% prednisolone eye drops three times daily for 7 weeks and their contralateral eyes treated with artificial tear preparation and that of two adult untreated Braford cows and untreated young calves eyes were analyzed with light and electron microscopy.
  • In the untreated Braford controls and in untreated calf eyes, plaques were nearly absent.
  • These changes were not seen in contralateral eyes or eyes of untreated animals.

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2229-38 [10892867.001]
  • [Cites] Am J Ophthalmol. 1967 Feb;63(2):283-9 [5335424.001]
  • [Cites] Exp Eye Res. 2003 Dec;77(6):757-65 [14609564.001]
  • [Cites] Arch Ophthalmol. 2004 Oct;122(10):1492-7 [15477461.001]
  • [Cites] Am J Ophthalmol. 1970 Apr;69(4):608-10 [5437825.001]
  • [Cites] Trans Am Ophthalmol Soc. 1969;67:339-54 [5381311.001]
  • [Cites] Exp Eye Res. 1973 Oct 10;17(1):19-31 [4356557.001]
  • [Cites] Trans Am Ophthalmol Soc. 1977;75:353-81 [613525.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1979 Sep;18(9):918-29 [113361.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1981 Oct;21(4):563-73 [7287346.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1981 Oct;21(4):574-85 [7287347.001]
  • [Cites] Trans Ophthalmol Soc U K. 1986;105 ( Pt 2):180-95 [3467494.001]
  • [Cites] Curr Eye Res. 1988 Aug;7(8):799-807 [3180831.001]
  • [Cites] Exp Eye Res. 1991 Jun;52(6):681-90 [1855543.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1992 Jun;33(7):2242-50 [1607235.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1993 Nov;34(12):3386-95 [8225873.001]
  • [Cites] Exp Eye Res. 1993 Oct;57(4):461-8 [8282032.001]
  • [Cites] Korean J Ophthalmol. 1996 Jun;10(1):29-33 [8755199.001]
  • [Cites] Arch Ophthalmol. 1997 Mar;115(3):375-83 [9076211.001]
  • [Cites] Ophthalmologica. 1997;211(3):140-6 [9176894.001]
  • [Cites] Exp Eye Res. 1998 Jun;66(6):731-8 [9657905.001]
  • [Cites] Int J Mol Med. 1998 Feb;1(2):339-46 [9852235.001]
  • [Cites] Singapore Med J. 1999 May;40(5):345-8 [10489493.001]
  • [Cites] Arch Ophthalmol. 1962 Dec;68:742-53 [13967694.001]
  • [Cites] Arch Ophthalmol. 1963 Oct;70:482-91 [14078870.001]
  • [Cites] Arch Ophthalmol. 1963 Oct;70:492-9 [14078871.001]
  • [Cites] Arch Ophthalmol. 1963 Oct;70:500-7 [14078872.001]
  • [Cites] Invest Ophthalmol. 1965 Apr;4:198-205 [14283013.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Sep;47(9):4042-9 [16936121.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2008 Jul;246(7):1021-8 [18386038.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1255-63 [18952927.001]
  • [Cites] Exp Eye Res. 2009 Apr;88(4):752-9 [18977348.001]
  • [Cites] Exp Eye Res. 2009 Apr;88(4):769-75 [19114037.001]
  • [Cites] Exp Eye Res. 2009 Nov;89(5):648-59 [19540832.001]
  • [Cites] Exp Eye Res. 2004 Nov;79(5):649-63 [15500824.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4419-26 [14507888.001]
  • (PMID = 20237246.001).
  • [ISSN] 1552-5783
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / EY13749; United States / NEI NIH HHS / EY / R01 EY013749; United States / NEI NIH HHS / EY / R03 EY016050; United States / NEI NIH HHS / EY / R01 EY000160; United States / NEI NIH HHS / EY / EY00160; United States / NEI NIH HHS / EY / EY016050
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Collagen Type VI; 0 / Glucocorticoids; 9PHQ9Y1OLM / Prednisolone
  • [Other-IDs] NLM/ PMC2910640
  •  go-up   go-down


16. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood; 2008 Feb 1;111(3):1060-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vorinostat (suberoylanilide hydroxamic acid, SAHA) is a histone deacetylase inhibitor active clinically in cutaneous T-cell lymphoma and preclinically in leukemia.
  • Patients with relapsed or refractory leukemias or myelodysplastic syndromes (MDS) and untreated patients who were not candidates for chemotherapy were eligible.
  • Of 41 patients, 31 had acute myeloid leukemia (AML), 4 chronic lymphocytic leukemia, 3 MDS, 2 acute lymphoblastic leukemia, and 1 chronic myelocytic leukemia.
  • [MeSH-major] Enzyme Inhibitors / therapeutic use. Histone Deacetylase Inhibitors. Hydroxamic Acids / therapeutic use. Leukemia / drug therapy. Leukemia / pathology. Myelodysplastic Syndromes / drug therapy. Myelodysplastic Syndromes / pathology
  • [MeSH-minor] Acetylation. Adolescent. Adult. Aged. Aged, 80 and over. Clinical Trials, Phase I as Topic. Dose-Response Relationship, Drug. Drug Tolerance. Drug-Related Side Effects and Adverse Reactions. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Histone Deacetylases / metabolism. Histones / metabolism. Humans. Male. Middle Aged. Neoplasm Staging


17. Rashtak S, Ettore MW, Homburger HA, Murray JA: Combination testing for antibodies in the diagnosis of coeliac disease: comparison of multiplex immunoassay and ELISA methods. Aliment Pharmacol Ther; 2008 Sep 15;28(6):805-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We compared the sensitivity, specificity and accuracy of MIA and ELISA methods for TTG and DGP antibodies in mainly adult untreated coeliac patients (n = 92) and controls (n = 124).

  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Dis Sci. 2008 Jun;53(6):1582-8 [17985240.001]
  • [Cites] Scand J Gastroenterol. 2007 Dec;42(12):1428-33 [17852878.001]
  • [Cites] Gastroenterology. 2001 Feb;120(3):636-51 [11179241.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Jun;13(6):635-7 [11434587.001]
  • [Cites] Clin Chem. 2001 Nov;47(11):2023-8 [11673371.001]
  • [Cites] J Clin Pathol. 2002 Jun;55(6):424-8 [12037023.001]
  • [Cites] J Clin Gastroenterol. 2003 Mar;36(3):219-21 [12590232.001]
  • [Cites] Rom J Gastroenterol. 2003 Jun;12(2):101-6 [12853995.001]
  • [Cites] Pathology. 2003 Aug;35(4):285-304 [12959764.001]
  • [Cites] Am J Gastroenterol. 2003 Sep;98(9):2027-33 [14499783.001]
  • [Cites] Clin Immunol. 2004 Mar;110(3):252-66 [15047203.001]
  • [Cites] Dig Dis Sci. 2004 Apr;49(4):546-50 [15185855.001]
  • [Cites] Clin Chem. 2004 Nov;50(11):2125-35 [15388634.001]
  • [Cites] Gastroenterology. 1992 Jan;102(1):330-54 [1727768.001]
  • [Cites] Neth J Med. 1998 Jul;53(1):15-9 [9718937.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):888-94 [10201452.001]
  • [Cites] Clin Chem. 2004 Dec;50(12):2370-5 [15472035.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4 Suppl 1):S52-6 [15825127.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4 Suppl 1):S74-8 [15825130.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Jun;19(3):389-400 [15925844.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2005 Jul;41(1):44-8 [15990629.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Sep;4(9):1112-7 [16860613.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1981-2002 [17087937.001]
  • [Cites] Ann N Y Acad Sci. 2007 Aug;1109:330-7 [17785322.001]
  • [Cites] Clin Exp Immunol. 2007 Nov;150(2):285-93 [17803713.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1731-43 [17960014.001]
  • [Cites] Clin Med Res. 2007 Oct;5(3):184-92 [18056028.001]
  • [Cites] Autoimmunity. 2008 Feb;41(1):116-21 [18176874.001]
  • [Cites] Clin Chem. 2007 Dec;53(12):2186-92 [17901114.001]
  • [Cites] Liver Int. 2008 Apr;28(4):467-76 [18339073.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):426-32; quiz 370 [18304884.001]
  • [Cites] J Clin Gastroenterol. 2008 May-Jun;42(5):460-5 [18344893.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2000 Nov;31(5):513-9 [11144436.001]
  • (PMID = 19145736.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK-057892; United States / NIDDK NIH HHS / DK / DK057892-07; United States / NIDDK NIH HHS / DK / R01 DK057892; United States / NIDDK NIH HHS / DK / R01 DK057892-07; United States / NIDDK NIH HHS / DK / R01 DK057892-08
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Immunoglobulin A; 0 / Immunoglobulin G
  • [Other-IDs] NLM/ NIHMS73354; NLM/ PMC2666354
  •  go-up   go-down


18. Laron Z, Ginsberg S, Webb M: Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion - preliminary report. Growth Horm IGF Res; 2008 Oct;18(5):434-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUBJECTS: We studied 11 untreated adult patients with LS (5M, 6F), five girls with LS treated by IGF-I and five adult patients with GH gene deletion (3M, 3F), four previously treated by hGH in childhood.
  • RESULTS: Six out of 11 adult patients with LS, two out of the five IGF-I treated girls with LS and three out of five adult hGH gene deletion patients were found to have NAFLD (nonalcoholic fatty liver disease).
  • CONCLUSION: NAFLD is a frequent complication in untreated and treated congenital IGF-I deficiency.
  • [MeSH-minor] Adult. Female. Humans. Insulin Resistance. Insulin-Like Growth Factor I / deficiency. Male. Middle Aged

  • Genetic Alliance. consumer health - Laron syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18462969.001).
  • [ISSN] 1096-6374
  • [Journal-full-title] Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • [ISO-abbreviation] Growth Horm. IGF Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


19. Leathwick DM, Miller CM, Atkinson DS, Haack NA, Waghorn TS, Oliver AM: Managing anthelmintic resistance: untreated adult ewes as a source of unselected parasites, and their role in reducing parasite populations. N Z Vet J; 2008 Aug;56(4):184-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Managing anthelmintic resistance: untreated adult ewes as a source of unselected parasites, and their role in reducing parasite populations.
  • AIMS: To test the hypotheses that when untreated adult ewes are rotationally grazed (follow behind) on pastures after lambs receiving routine anthelmintic treatments, the ewes can function as a source of unselected parasites in refugia, capable of slowing the development of anthelmintic resistance, and suppress the build-up of parasites resulting from the development of anthelmintic resistance.
  • METHODS: Firstly, the potential of untreated adult ewes to slow the development of anthelmintic resistance, and to suppress parasite populations under differing levels of anthelmintic efficacy, was investigated using a simulation model.
  • RESULTS: Model simulations indicated that parasites cycling in the untreated ewes could slow the development of resistance being selected for by the anthelmintic treatments given to lambs and this could occur without a nett increase in larval numbers on pasture.
  • In the field trial, untreated adult ewes contributed to pasture infestations of most parasite species, but not Nematodirus spp.
  • CONCLUSIONS: Untreated adult ewes were a source of unselected genotypes, capable of slowing the development of anthelmintic resistance in most, but not all, parasite species.
  • Further, the potential of adult ewes to remove from pasture more parasite larvae than they contribute through faecal contamination indicates a potentially useful role in suppressing parasite populations, particularly when worm control in lambs is less effective as a result of anthelmintic resistance.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18690255.001).
  • [ISSN] 0048-0169
  • [Journal-full-title] New Zealand veterinary journal
  • [ISO-abbreviation] N Z Vet J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anthelmintics
  •  go-up   go-down


20. Rakusan D, Kujal P, Kramer HJ, Husková Z, Vanourková Z, Vernerová Z, Mrázová I, Thumová M, Cervenka L, Vanecková I: Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. Am J Physiol Renal Physiol; 2010 Oct;299(4):F758-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effects of the human renin inhibitor aliskiren on blood pressure (BP), end-organ damage, proteinuria, and tissue and plasma angiotensin (ANG) II levels in young and adult heterozygous Ren-2 transgenic rats (TGR) were evaluated and compared with the effect of the ANG type 1 (AT(1)) receptor blocker losartan during treatment and after 12 days after the withdrawal of drug treatments.
  • BP was monitored by telemetry from the age of 32 days on (young rats) and at 100 days (adult rats).
  • Aliskiren (10 mg·kg(-1)·day(-1) in osmotic minipumps) or losartan (5 mg·kg(-1)·day(-1) in drinking water) treatment was applied for 28 days in young rats and for 70 days in adult rats.
  • In young untreated TGR, severe hypertension rapidly evolved.
  • Adult untreated TGR exhibited stable established hypertension.
  • Both aliskiren and losartan fully prevented the development of hypertension and cardiac hypertrophy in young TGR and normalized BP and cardiac hypertrophy in adult TGR.
  • After cessation of aliskiren treatment in both young and adult TGR BP and cardiac hypertrophy were persistently reduced, while after losartan withdrawal BP and cardiac hypertrophy rapidly increased.
  • In adult aliskiren-treated rats proteinuria was significantly reduced compared with losartan (the effect persisting after withdrawal of treatment), and this decrease strongly correlated with normalization of glomerular size in these animals.

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • Hazardous Substances Data Bank. Losartan .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20668096.001).
  • [ISSN] 1522-1466
  • [Journal-full-title] American journal of physiology. Renal physiology
  • [ISO-abbreviation] Am. J. Physiol. Renal Physiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amides; 0 / Antihypertensive Agents; 0 / Fumarates; 0 / Ren2 protein, rat; 11128-99-7 / Angiotensin II; 502FWN4Q32 / aliskiren; EC 3.4.23.15 / Renin; JMS50MPO89 / Losartan
  •  go-up   go-down


21. Hacıhanefioğlu A, Tarkun P, Gonullu E, Vardar O: Lymphomas of Waldeyer's ring: Clinical features, management and prognosis of eleven adult patients. Turk J Haematol; 2008 Jun 5;25(2):75-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomas of Waldeyer's ring: Clinical features, management and prognosis of eleven adult patients.
  • Between 1999 and 2006, the medical records and pathology data of all newly diagnosed, previously untreated adult patients with Waldeyer's ring lymphomas were retrospectively reviewed.
  • This series characterized the clinicopathologic features and outcomes of adult patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27264443.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


22. Rees J, Watt H, Jäger HR, Benton C, Tozer D, Tofts P, Waldman A: Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation. Eur J Radiol; 2009 Oct;72(1):54-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation.
  • Adult low-grade gliomas (LGG) grow slowly, but most eventually undergo malignant transformation.
  • Twenty-seven patients with biopsy-proven, untreated LGG had at least three MRI studies at 6 monthly intervals.
  • [MeSH-minor] Adult. Aged. Cell Transformation, Neoplastic / pathology. Female. Humans. Image Enhancement / methods. Male. Middle Aged. Reproducibility of Results. Risk Assessment. Risk Factors. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18632238.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


23. Wiśniewski A, Milde K, Stupnicki R: [Spontaneous growth of girls with Turner's syndrome until 6 years of age]. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006;12(1):7-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A marked short stature is a prime symptom of the disease, the average adult body height of untreated women being by 23 cm lower than that of healthy ones.
  • At the age of 6 years, the average difference in body height between Turner and healthy girls exceeds 1/3 of the final growth deficit noted in untreated adult women with TS.

  • MedlinePlus Health Information. consumer health - Developmental Disabilities.
  • MedlinePlus Health Information. consumer health - Turner Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16704855.001).
  • [ISSN] 1234-625X
  • [Journal-full-title] Endokrynologia, diabetologia i choroby przemiany materii wieku rozwojowego : organ Polskiego Towarzystwa Endokrynologów Dziecięcych
  • [ISO-abbreviation] Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


24. Tageja N, Mohammad M, Bentley G, Bishop C: Adult T-Cell Leukemia/Lymphoma with CLL-Like Morphology-A Case Report. Case Rep Med; 2010;2010:729790
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-Cell Leukemia/Lymphoma with CLL-Like Morphology-A Case Report.
  • Adult T-cell Leukemia/Lymphoma (ATL) is rarely seen in the U.S. and Europe, usually limited to African Americans from the southeastern U.S. and immigrants from HTLV-1 endemic areas.
  • We present a case of chronic adult T-cell leukemia (ATL) with Chronic Lymphocytic Leukemia- (CLL-) like morphology that remained untreated for ten years and then developed treatment refractory acute ATL crisis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1994 Feb;86(2):383-5 [8199030.001]
  • [Cites] Br J Haematol. 1999 May;105(2):369-75 [10233406.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1373-7 [18042693.001]
  • [Cites] Leuk Lymphoma. 1993 Dec;12(1-2):123-30 [8161929.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] J Clin Pathol. 1989 Jun;42(6):567-84 [2738163.001]
  • [Cites] Eur J Haematol. 2008 Mar;80(3):185-96 [18081707.001]
  • (PMID = 20368783.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2846349
  •  go-up   go-down


25. Gutiérrez LP, Kołtowska-Häggström M, Jönsson PJ, Mattsson AF, Svensson D, Westberg B, Luger A: Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiol Drug Saf; 2008 Jan;17(1):90-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study was based on 11,374 treated (40,000 patient-years of observation) and 263 untreated adult GH deficient patients from 30 countries, in whom background characteristics, clinical values such as lipids and body composition, quality of life (QoL) and GH dosage as well as safety profile were evaluated.
  • RESULTS: The study depicts the clinical picture of adult patients with GH deficiency managed in current clinical settings.
  • [MeSH-minor] Adult. Body Composition / drug effects. Cholesterol / blood. Evidence-Based Medicine. Female. Humans. Male. Prospective Studies. Quality of Life. Recombinant Proteins. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17957812.001).
  • [ISSN] 1053-8569
  • [Journal-full-title] Pharmacoepidemiology and drug safety
  • [ISO-abbreviation] Pharmacoepidemiol Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 12629-01-5 / Human Growth Hormone; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


26. Winquist E, Knox J, Ayoub JP, Wood L, Wainman N, Reid GK, Pearce L, Shah A, Eisenhauer E: Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest New Drugs; 2006 Mar;24(2):159-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Untreated adult patients with measurable MRC were treated with MG98 at a dose of 360 mg/m2 via 2-h iv infusion twice weekly for three consecutive weeks out of four.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Canada. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. RNA, Messenger / blood

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2001 Dec 6;345(23 ):1655-9 [11759643.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Biol Chem. 1986 Feb 5;261(4):1594-8 [2418016.001]
  • [Cites] Invest New Drugs. 2003 Feb;21(1):85-97 [12795533.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):672-83 [12424069.001]
  • [Cites] Lancet. 2001 Sep 22;358(9286):966-70 [11583750.001]
  • [Cites] J Urol. 2002 Jul;168(1):239-47 [12050550.001]
  • [Cites] J Cell Biochem Suppl. 2000;Suppl 35:78-83 [11389535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7504-9 [11390984.001]
  • [Cites] Ann Oncol. 2003 May;14(5):766-74 [12702532.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9700-4 [7937876.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3854-61 [15897586.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10 (21):7244-51 [15534098.001]
  • [Cites] Nephron. 1976;16(1):31-41 [1244564.001]
  • [Cites] Lancet. 1999 Jan 2;353(9146):14-7 [10023944.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3920-7 [11751483.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):679-83 [11895895.001]
  • [Cites] N Engl J Med. 1998 Apr 30;338(18):1265-71 [9562580.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2859-67 [10561363.001]
  • [Cites] Nat Med. 1995 Jul;1(7):686-92 [7585152.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5048-57 [15297406.001]
  • (PMID = 16502349.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DMAP1 protein, human; 0 / MG 98 phosphorothioate antisense oligodeoxynucleotide; 0 / Oligodeoxyribonucleotides; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / Thionucleotides
  •  go-up   go-down


27. Rödel S, Engert A, Diehl V, Reiser M: Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long-term survival in patients with aggressive malignant non-Hodgkin's lymphomas: long-term follow-up of a pilot study. Leuk Lymphoma; 2005 Dec;46(12):1729-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Untreated adult patients with aggressive NHL, presenting with Ann Arbour stage II-IV disease or stage I with bulky disease, and with at least one of the following risk factors: age > 60 years, advanced disease, elevated serum lactate dehydrogenase level, Eastern Cooperative Oncology Group (ECOG) performance status >or= 2, presence of extranodal sites of disease and bulky disease, were treated with the ACOMED regimen consisting of 4-6 cycles of adriamycin 25 mg/m(2) i.v. on days 4-5, cyclophosphamide 250 mg/m(2) i.v. on days 1-5, vincristine 2 mg i.v. absolute on day 1, methotrexate 500 mg/m(2) i.v. on day 1 with leucovorin-rescue after 24 h 30 mg/m(2) i.v. and 3 x 15 mg p.o., etoposide 100 mg/m(2) i.v. on days 3-5, dexamethasone 10 mg/m(2) p.o. on days 1-5 and granulocyte colony-stimulating factor support, repeated on day 21.
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Radiotherapy / adverse effects. Survival Analysis. Survivors. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353313.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


28. Vieira TC, da Silva MR, Abucham J: The natural history of the R120C PROP1 mutation reveals a wide phenotypic variability in two untreated adult brothers with combined pituitary hormone deficiency. Endocrine; 2006 Dec;30(3):365-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The natural history of the R120C PROP1 mutation reveals a wide phenotypic variability in two untreated adult brothers with combined pituitary hormone deficiency.
  • METHODS: Clinical follow-up and molecular analysis of PROP1 in two adult brothers with CPHD, born from consanguineous parents, and not treated until late adulthood.
  • [MeSH-minor] Adult. Brazil. DNA Mutational Analysis. Humans. Male. Mutation, Missense. Phenotype

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2002 Dec;71(6):1450-5 [12428212.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1317-22 [15613419.001]
  • [Cites] Gene. 2001 Mar 7;265(1-2):61-9 [11255008.001]
  • [Cites] Gene Expr Patterns. 2004 Dec;5(2):279-84 [15567726.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):38-44 [12519826.001]
  • [Cites] AJR Am J Roentgenol. 2000 Feb;174(2):555-9 [10658742.001]
  • [Cites] Clin Genet. 2000 May;57(5):337-46 [10852367.001]
  • [Cites] Am J Hum Genet. 2005 May;76(5):833-49 [15800844.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Aug;57(2):283-91 [12153609.001]
  • [Cites] Nat Rev Genet. 2006 Apr;7(4):277-82 [16534515.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2005;6:237-60 [16124861.001]
  • [Cites] J Biol Chem. 2005 Nov 11;280(45):37572-84 [16157593.001]
  • [Cites] Adv Data. 2000 Jun 8;(314):1-27 [11183293.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Nov;87(11):5076-84 [12414875.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10604-9 [16009939.001]
  • [Cites] Mol Endocrinol. 1996 Dec;10(12):1570-81 [8961267.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Feb;62(2):163-8 [15670191.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4529-35 [11549703.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4556-61 [11134108.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3346-9 [9745452.001]
  • [Cites] Science. 1992 Aug 21;257(5073):1115-8 [1509262.001]
  • [Cites] Horm Res. 2003;60(5):227-31 [14614227.001]
  • [Cites] Arch Dis Child. 1970 Feb;45(239):13-23 [5440182.001]
  • [Cites] Nat Genet. 1998 Feb;18(2):147-9 [9462743.001]
  • [Cites] J Clin Endocrinol Metab. 1999 May;84(5):1645-50 [10323394.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Oct;83(10):3727-34 [9768691.001]
  • [Cites] Nat Genet. 1998 Jun;19(2):125-33 [9620767.001]
  • [Cites] FEBS Lett. 1998 Oct 23;437(3):216-20 [9824293.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):390-7 [10634415.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Oct;89(10):5256-65 [15472232.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Mar;84(3):942-5 [10084575.001]
  • [Cites] Eur J Endocrinol. 2000 Sep;143(3):347-52 [11022176.001]
  • [Cites] Nature. 1996 Nov 28;384(6607):327-33 [8934515.001]
  • (PMID = 17526949.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Pituitary Hormones; 0 / Prophet of Pit-1 protein
  •  go-up   go-down






Advertisement